PUBLIC COMPANY
save$XENEXenon Pharmaceuticals Inc.
$XENE59.73-4.16%Burnaby, British Columbia, Canadaupdated 5h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3An Open-label Study of XEN1101 in Epilepsy
- phase3A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- phase3An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
- phase3An Open-Label Study of Azetukalner in Major Depressive Disorder
- phase3A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
- phase3A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- phase3A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
- phase3A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 13, 26SELLMORTIMER IAN· PRESIDENT & CEO−$404K↗
- Mar 13, 26SELLKENNEY CHRISTOPHER JOHN· Chief Medical Officer−$78K↗
- Mar 13, 26SELLDiFabio Andrea· Chief Legal Officer−$74K↗
- Mar 10, 26SELLMORTIMER IAN· PRESIDENT & CEO−$677K↗
- Mar 10, 26SELLKENNEY CHRISTOPHER JOHN· Chief Medical Officer−$167K↗
- Mar 10, 26SELLDiFabio Andrea· Chief Legal Officer−$157K↗
- Mar 9, 26SELLMORTIMER IAN· PRESIDENT & CEO−$4.03M↗
- Mar 9, 26SELLMORTIMER IAN· PRESIDENT & CEO−$3.70M↗
- Mar 9, 26SELLMORTIMER IAN· PRESIDENT & CEO−$2.57M↗
- Mar 9, 26SELLMORTIMER IAN· PRESIDENT & CEO−$1.90M↗
- Mar 9, 26SELLMORTIMER IAN· PRESIDENT & CEO−$1.30M↗
- Mar 9, 26SELLMORTIMER IAN· PRESIDENT & CEO−$1.28M↗
- Mar 9, 26SELLMORTIMER IAN· PRESIDENT & CEO−$743K↗
- Mar 9, 26SELLMORTIMER IAN· PRESIDENT & CEO−$609K↗
- Mar 9, 26SELLMORTIMER IAN· PRESIDENT & CEO−$150K↗
routine RSU / option mechanics (5)
- Mar 12, 26option exerciseKENNEY CHRISTOPHER JOHN · Chief Medical Officer3,750 sh
- Mar 12, 26option exerciseMORTIMER IAN · PRESIDENT & CEO12,500 sh
- Mar 12, 26option exerciseMORTIMER IAN · PRESIDENT & CEO12,500 sh
- Mar 12, 26option exerciseDiFabio Andrea · Chief Legal Officer3,750 sh
- Mar 12, 26option exerciseDiFabio Andrea · Chief Legal Officer3,750 sh
🐶 Hiring Signal
News
- NewLimit’s $435M megaround; Lilly’s busy dealmaking weekThe anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.biopharma_dive · 2mo ago
- A year after Vertex’s big launch, pain drug research faces a pivotal momentJournavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?biopharma_dive · 3mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that